Vladimir S Kostic

List of Publications by Year
in descending order

126	2,800	218677	233421
papers	citations	26 h-index	45 g-index

133	133	133	4611
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Cognitive impairment in multiple system atrophy: A position statement by the neuropsychology task force of the MDS multiple system atrophy (MODIMSA) study group. Movement Disorders, 2014, 29, 857-867.	3.9	193
2	Efficient neuroplasticity induction in chronic stroke patients by an associative brain-computer interface. Journal of Neurophysiology, 2016, 115, 1410-1421.	1.8	189
3	Brain structural and functional connectivity in <scp>P</scp>arkinson's disease with freezing of gait. Human Brain Mapping, 2015, 36, 5064-5078.	3.6	154
4	Artificial intelligence for assisting diagnostics and assessment of Parkinsonâ€™s diseaseâ€”A review. Clinical Neurology and Neurosurgery, 2019, 184, 105442.	1.4	110
5	The protective role of AMP-activated protein kinase in alpha-synuclein neurotoxicity in vitro. Neurobiology of Disease, 2014, 63, 1-11.	4.4	97
6	Cortico-striatal-thalamic network functional connectivity in hemiparkinsonism. Neurobiology of Aging, 2014, 35, 2592-2602.	3.1	77
7	Structural Brain Connectome and Cognitive Impairment in Parkinson Disease. Radiology, 2017, 283, 515-525.	7.3	77
8	Cognitive Impairment in Myotonic Dystrophy Type 1 Is Associated with White Matter Damage. PLoS ONE, 2014, 9, e104697.	2.5	76
9	A critique of the second consensus criteria for multiple system atrophy. Movement Disorders, 2019, 34, 975-984.	3.9	73
10	Mutations inGNAL. JAMA Neurology, 2014, 71, 490.	9.0	70
11	Suicide and suicidal ideation in Parkinson's disease. Journal of the Neurological Sciences, 2010, 289, 40-43.	0.6	67
12	Neuroanatomical correlates of depression and apathy in Parkinson's disease: Magnetic resonance imaging studies. Journal of the Neurological Sciences, 2011, 310, 61-63.	0.6	58
13	Multiparametric MRI to distinguish early onset Alzheimer's disease and behavioural variant of frontotemporal dementia. NeuroImage: Clinical, 2017, 15, 428-438.	2.7	49
14	Circumstances of falls and fall-related injuries among patients with Parkinson's disease in an outpatient setting. Geriatric Nursing, 2014, 35, 364-369.	1.9	42
15	Longitudinal assessment of autonomic dysfunction in early Parkinson's disease. Parkinsonism and Related Disorders, 2019, 66, 74-79.	2.2	40
16	Tracking Cortical Changes Throughout Cognitive Decline in Parkinson's Disease. Movement Disorders, 2020, 35, 1987-1998.	3.9	39
17	Longitudinal brain connectivity changes and clinical evolution in Parkinsonâ€™s disease. Molecular Psychiatry, 2021, 26, 5429-5440.	7.9	39
18	Finger tapping analysis in patients with Parkinsonâ€™s disease and atypical parkinsonism. Journal of Clinical Neuroscience, 2016, 30, 49-55.	1.5	37

#	Article	IF	Citations
19	C9orf72 expansion as a possible genetic cause of Huntington disease phenocopy syndrome. Journal of Neurology, 2014, 261, 1917-1921.	3.6	34
20	Progressive brain atrophy and clinical evolution in Parkinsonâ€™s disease. NeuroImage: Clinical, 2020, 28, 102374.	2.7	33
21	Brain Structural Changes in Focal Dystoniaâ€"What About Task Specificity? A Multimodal <scp>MRI</scp> Study. Movement Disorders, 2021, 36, 196-205.	3.9	33
22	Gait characteristics in patients with major depression performing cognitive and motor tasks while walking. Psychiatry Research, 2014, 217, 39-46.	3.3	32
23	Role of habenula and amygdala dysfunction in Parkinson disease patients with punding. Neurology, 2017, 88, 2207-2215.	1.1	32
24	Interplay between Matrix Metalloproteinase-9, Matrix Metalloproteinase-2, and Interleukins in Multiple Sclerosis Patients. Disease Markers, 2016, 2016, 1-9.	1.3	31
25	Near-falls in people with Parkinson's disease: Circumstances, contributing factors and association with falling. Clinical Neurology and Neurosurgery, 2017, 161, 51-55.	1.4	29
26	Unraveling ALS due to SOD1 mutation through the combination of brain and cervical cord MRI. Neurology, 2018, 90, e707-e716.	1.1	29
27	An Expert System for Quantification of Bradykinesia Based on Wearable Inertial Sensors. Sensors, 2019, 19, 2644.	3.8	25
28	Multiple Sclerosis as the Cause of Sudden â€˜Pontineâ€™ Deafness. International Journal of Audiology, 1994, 33, 195-201.	1.7	24
29	Brain structural changes in spasmodic dysphonia: A multimodal magnetic resonance imaging study. Parkinsonism and Related Disorders, 2016, 25, 78-84.	2.2	24
30	Selection of gait parameters for differential diagnostics of patients with de novo Parkinsonâ€™s disease. Neurological Research, 2017, 39, 853-861.	1.3	24
31	Cognitive impairment and structural brain damage in multiple system atrophy-parkinsonian variant. Journal of Neurology, 2020, 267, 87-94.	3.6	24
32	Longitudinal clinical, cognitive, and neuroanatomical changes over 5 years in GBA-positive Parkinsonâ€™s disease patients. Journal of Neurology, 2022, 269, 1485-1500.	3.6	24
33	Functional and structural brain networks in posterior cortical atrophy: A two-centre multiparametric MRI study. NeuroImage: Clinical, 2018, 19, 901-910.	2.7	23
34	Quality of life in patients with progressive supranuclear palsy: one-year follow-up. Journal of Neurology, 2015, 262, 2042-2048.	3.6	22
35	Indoor and outdoor falls in persons with Parkinsonâ€™s disease after 1Âyear follow-up study: differences and consequences. Neurological Sciences, 2016, 37, 597-602.	1.9	22
36	White matter tract alterations in Parkinson's disease patients with punding. Parkinsonism and Related Disorders, 2017, 43, 85-91.	2.2	22

#	Article	IF	Citations
37	Quantification of Finger-Tapping Angle Based on Wearable Sensors. Sensors, 2017, 17, 203.	3.8	22
38	Are there two different forms of functional dystonia? A multimodal brain structural MRI study. Molecular Psychiatry, 2020, 25, 3350-3359.	7.9	22
39	Treatment of young-onset Parkinson's disease: role of dopamine receptor agonists. Parkinsonism and Related Disorders, 2009, 15, S71-S75.	2.2	21
40	Phenotype of non-c.907_909delGAG mutations in TOR1A: DYT1 dystonia revisited. Parkinsonism and Related Disorders, 2015, 21, 1256-1259.	2.2	21
41	Genomic variants in the FTO gene are associated with sporadic amyotrophic lateral sclerosis in Greek patients. Human Genomics, 2017, 11, 30.	2.9	21
42	Transcranial sonography in pantothenate kinase-associated neurodegeneration. Journal of Neurology, 2012, 259, 959-964.	3.6	20
43	Exclusion of linkage to chromosomes 14q, 2q37 and 8p21.1-q11.23 in a Serbian family with idiopathic basal ganglia calcification. Journal of Neurology, 2011, 258, 1637-1642.	3.6	19
44	Recurrent falls in Parkinsonâ€™s disease after one year of follow-up: A nested case-control study. Archives of Gerontology and Geriatrics, 2016, 65, 17-24.	3.0	19
45	Pattern of disease progression in atypical form of pantothenate-kinase-associated neurodegeneration (PKAN) â€“ Prospective study. Parkinsonism and Related Disorders, 2015, 21, 521-524.	2.2	18
46	The spread of primary late-onset focal dystonia in a long-term follow up study. Clinical Neurology and Neurosurgery, 2015, 132, 41-43.	1.4	18
47	Brain Calcification and Movement Disorders. Current Neurology and Neuroscience Reports, 2017, 17, 2.	4.2	18
48	Tracking brain damage in progressive supranuclear palsy: a longitudinal MRI study. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 696-701.	1.9	18
49	Mutations in Niemann Pick type C gene are risk factor for Alzheimerâ€™s disease. Medical Hypotheses, 2014, 83, 559-562.	1.5	17
50	Axial motor clues to identify atypical parkinsonism: A multicentre European cohort study. Parkinsonism and Related Disorders, 2018, 56, 33-40.	2.2	17
51	Intrafamilial phenotypic and genetic heterogeneity of dystonia. Journal of the Neurological Sciences, 2006, 250, 92-96.	0.6	16
52	AMP-activated protein kinase inhibits MPP+-induced oxidative stress and apoptotic death of SH-SY5Y cells through sequential stimulation of Akt and autophagy. European Journal of Pharmacology, 2019, 863, 172677.	3.5	16
53	Chemical management of levodopa-induced dyskinesia in Parkinsonâ€™s disease patients. Expert Opinion on Pharmacotherapy, 2019, 20, 219-230.	1.8	16
54	Breakdown of the affectiveâ€cognitive network in functional dystonia. Human Brain Mapping, 2020, 41, 3059-3076.	3.6	16

#	Article	IF	Citations
55	Longitudinal White Matter Damage Evolution in Parkinson's Disease. Movement Disorders, 2022, 37, 315-324.	3.9	16
56	Attentional Set-Shifting in Parkinsonâ€™s Disease Patients with Freezing of Gait-Acquisition and Discrimination Set Learning Deficits at the Background?. Journal of the International Neuropsychological Society, 2014, 20, 929-936.	1.8	15
57	The role of mutations in COL6A3 in isolated dystonia. Journal of Neurology, 2016, 263, 730-734.	3.6	15
58	10Kin1day: A Bottom-Up Neuroimaging Initiative. Frontiers in Neurology, 2019, 10, 425.	2.4	15
59	Dynamics of impulsiveâ€“compulsive behaviors in early Parkinsonâ€™s disease: a prospective study. Journal of Neurology, 2020, 267, 1127-1136.	3.6	15
60	Leber hereditary optic neuropathy in the population of Serbia. European Journal of Paediatric Neurology, 2014, 18, 354-359.	1.6	14
61	Presenting symptoms of GBA-related Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 804-807.	2.2	14
62	Linking Penetrance and Transcription in <scp>DYTâ€¶HAP1</scp>: Insights From a Human <scp>iPSC</scp>â€Derived Cortical Model. Movement Disorders, 2021, 36, 1381-1391.	3.9	14
63	Decreased Insulin Sensitivity and Impaired Fibrinolytic Activity in Type 2 Diabetes Patients and Nondiabetics with Ischemic Stroke. International Journal of Endocrinology, 2015, 2015, 1-7.	1.5	13
64	GCH1 mutations are common in Serbian patients with dystonia-parkinsonism: Challenging previously reported prevalenceÂrates of DOPA-responsive dystonia. Parkinsonism and Related Disorders, 2017, 45, 81-84.	2.2	13
65	Influence of attention alternation on movement-related cortical potentials in healthy individuals and stroke patients. Clinical Neurophysiology, 2017, 128, 165-175.	1.5	13
66	Progression of white matter damage in progressive supranuclear palsy with predominant parkinsonism. Parkinsonism and Related Disorders, 2018, 49, 95-99.	2.2	13
67	Seemingly dominant inheritance of a recessiveANO10mutation in romani families with cerebellar ataxia. Movement Disorders, 2016, 31, 1929-1931.	3.9	12
68	Is there a specific psychiatric background or personality profile in functional dystonia?. Journal of Psychosomatic Research, 2017, 97, 58-62.	2.6	12
69	Pharmacokinetic drug evaluation of opicapone for the treatment of Parkinsonâ€™s disease. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 353-360.	3.3	12
70	Use of the Neuropsychiatric Inventory to Characterize the Course of Neuropsychiatric Symptoms in Progressive Supranuclear Palsy. Journal of Neuropsychiatry and Clinical Neurosciences, 2018, 30, 38-44.	1.8	12
71	Health-related quality of life in patients with Parkinson's disease: Implications for falling. Parkinsonism and Related Disorders, 2015, 21, 573-576.	2.2	11
72	Neuropsychiatric symptoms in Serbian patients with Parkinson's disease. Journal of the Neurological Sciences, 2016, 367, 342-346.	0.6	11

#	Article	IF	Citations
73	Finger and foot tapping sensor system for objective motor assessment. Vojnosanitetski Pregled, 2018, 75, 68-77.	0.2	11
74	Reversible lesions in the brain parenchyma in Wilsonâ€²s disease confirmed by magnetic resonance imaging: earlier administration of chelating therapy can reduce the damage to the brain. Neural Regeneration Research, 2014, 9, 1912.	3.0	11
75	The clinical syndrome of dystonia with anarthria/aphonia. Parkinsonism and Related Disorders, 2016, 24, 20-27.	2.2	10
76	Characteristics of two distinct clinical phenotypes of functional (psychogenic) dystonia: follow-up study. Journal of Neurology, 2018, 265, 82-88.	3.6	10
77	The Status of SCA1, MJD/SCA3, FRDA, DRPLA and MD Triplet Containing Genes in Patients with Huntington Disease and Healthy Controls. Journal of Neurogenetics, 2000, 14, 257-263.	1.4	9
78	Bereitschaftspotential in depressed and non-depressed patients with Parkinson's disease. Movement Disorders, 2001, 16, 294-300.	3.9	9
79	Excellent outcome of pallidal deep brain stimulation in DYT6 dystonia: A case report. Journal of the Neurological Sciences, 2016, 366, 18-19.	0.6	9
80	HPCA-related dystonia: Too rare to be found?. Movement Disorders, 2016, 31, 1071-1071.	3.9	9
81	Analysis of secondary mtDNA mutations in families with Leberâ€™s hereditary optic neuropathy: Four novel variants and their association with clinical presentation. Mitochondrion, 2020, 50, 132-138.	3.4	9
82	Oxidative Stress Profile in Genetically Confirmed Cases of Leberâ€™s Hereditary Optic Neuropathy. Journal of Molecular Neuroscience, 2021, 71, 1070-1081.	2.3	9
83	Functional connectivity in Parkinsonâ€™s disease candidates for deep brain stimulation. Npj Parkinson's Disease, 2022, 8, 4.	5.3	9
84	Dynamics of change in self-reported disability among persons with Parkinsonâ€™s disease after 2Âyears of follow-up. Neurological Sciences, 2017, 38, 1415-1421.	1.9	8
85	Quantitative and qualitative gait assessments in Parkinsonâ€™s disease patients. Vojnosanitetski Pregled, 2014, 71, 809-816.	0.2	8
86	Function of dopamine receptors in young-onset parkinson's disease: Prolactin response. Movement Disorders, 1993, 8, 227-229.	3.9	7
87	Identification of novel variants in LRRK2 gene in patients with Parkinson's disease in Serbian population. Journal of the Neurological Sciences, 2015, 353, 59-62.	0.6	7
88	Healthâ€related quality of life as a predictor of recurrent falling in Parkinson's disease: 1â€year followâ€up study. Psychogeriatrics, 2016, 16, 362-367.	1.2	7
89	Psychiatric Symptoms in the Initial Motor Stage of Parkinson's Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2016, 28, 205-210.	1.8	7
90	Analysis of on-surface and in-air movement in handwriting of subjects with Parkinsonâ€™s disease and atypical parkinsonism. Biomedizinische Technik, 2019, 64, 187-194.	0.8	7

#	Article	IF	Citations
91	Change in fear of falling in Parkinson's disease: a two-year prospective cohort study. International Psychogeriatrics, 2019, 31, 13-20.	1.0	7
92	Fluoxetine does not impair motor function in patients with Parkinson's disease: Correlation between mood and motor functions with plasma concentrations of fluoxetine/norfluoxetine. Vojnosanitetski Pregled, 2012, 69, 1067-1075.	0.2	7
93	Glucocerebrosidase and parkinsonism: lessons to learn. Journal of Neurology, 2016, 263, 1033-1044.	3.6	6
94	Factors associated with deterioration of health-related quality of life in multiple system atrophy: 1-year follow-up study. Acta Neurologica Belgica, 2018, 118, 589-595.	1.1	6
95	Functional MRI connectivity of the primary motor cortex in functional dystonia patients. Journal of Neurology, 2022, 269, 2961-2971.	3.6	6
96	NBIA Syndromes: A Step Forward from the Previous Knowledge. Neurology India, 2021, 69, 1380-1388.	0.4	6
97	Spatiotemporal gait characteristics of Huntingtonâ€™s disease during dual-task walking. International Journal of Neuroscience, 2020, 130, 136-143.	1.6	5
98	Autosomal recessive adultÂonset ataxia. Journal of Neurology, 2022, 269, 504-533.	3.6	5
99	Changes of Phenotypic Pattern in Functional Movement Disorders: A Prospective Cohort Study. Frontiers in Neurology, 2020, 11, 582215.	2.4	5
100	Whole Mitochondrial Genome Analysis in Serbian Cases of Leberâ€™s Hereditary Optic Neuropathy. Genes, 2020, 11, 1037.	2.4	4
101	The Profile and Evolution of Neuropsychiatric Symptoms in Multiple System Atrophy: Self- and Caregiver Report. Journal of Neuropsychiatry and Clinical Neurosciences, 2021, 33, 124-131.	1.8	4
102	Clinical and Genetic Analysis of Psychosis in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2021, 11, 1973-1980.	2.8	4
103	Neurogenetic traits outline vulnerability to cortical disruption in Parkinsonâ€™s disease. NeuroImage: Clinical, 2022, 33, 102941.	2.7	4
104	Lack of Accredited Clinical Training in Movement Disorders in Europe, Egypt, and Tunisia. Journal of Parkinson's Disease, 2020, 10, 1833-1843.	2.8	3
105	Leber's Hereditary Optic Neuropathy: Novel Views and Persisting Challenges. CNS and Neurological Disorders - Drug Targets, 2018, 16, 927-935.	1.4	3
106	Fluoxetine does not impair motor function in patients with Parkinson's disease: correlation between mood and motor functions with plasma concentrations of fluoxetine/norfluoxetine. Vojnosanitetski Pregled, 2012, 69, 1067-75.	0.2	3
107	In silico model of mtDNA mutations effect on secondary and 3D structure of mitochondrial rRNA and tRNA in Leberâ€™s hereditary optic neuropathy. Experimental Eye Research, 2020, 201, 108277.	2.6	2
108	Brain structural alterations in patients with GCH1 mutations associated DOPA-responsive dystonia. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 332-333.	1.9	2

#	Article	IF	Citations
109	PHACTR1 genetic variability is not critical in small vessel ischemic disease patients and PcomA recruitment in C57BL/6J mice. Scientific Reports, 2021, 11, 6072.	3.3	2
110	Spectral parameters for finger tapping quantification. Facta Universitatis - Series Electronics and Energetics, 2017, 30, 585-597.	0.9	2
111	Mutational Analysis and mtDNA Haplogroup Characterization in Three Serbian Cases of Mitochondrial Encephalomyopathies and Literature Review. Diagnostics, 2021, 11, 1969.	2.6	2
112	Adherence to Medication among Parkinsonâ€™s Disease Patients Using the Adherence to Refills and Medications Scale. International Journal of Clinical Practice, 2022, 2022, 1-7.	1.7	2
113	Reply: MRI measurements of brain stem structures in patients with Richardson's syndrome, progressive supranuclear palsyâ€“parkinsonism, and Parkinson's disease. Movement Disorders, 2011, 26, 1575-1576.	3.9	1
114	Premutations in the FMR1 gene in Serbian patients with undetermined tremor, ataxia and parkinsonism. Neurological Research, 2021, 43, 321-326.	1.3	1
115	Phenotypic expression and founder effect of PANK2 c.1583C>T (p.T528M) mutation in Serbian pantothenate kinase-associated neurodegeneration patients. Archives of Biological Sciences, 2019, 71, 275-280.	0.5	1
116	The correlation between genetic factors and freezing of gait in patients with Parkinson's disease. Parkinsonism and Related Disorders, 2022, 98, 7-12.	2.2	1
117	Clinical exome sequencing in Serbian patients with movement disorders: Single centre experience. Genetika, 2022, 54, 395-409.	0.4	1
118	The potential of imagination and artificial afference in stroke rehabilitation. , 2012, , .		0
119	O2-07-06: DISTINCT NEUROPSYCHOLOGICAL AND BEHAVIOURAL PROFILES IN EARLY-ONSET ALZHEIMER'S DISEASE: REPORT FROM BELGRADE MEMORY CLINIC. , 2014, 10, P179-P179.		0
120	[P1â€“563]: REPORT FROM BELGRADE DEMENTIA CENTER: A STEP TOWARD IMPROVING THE QUALITY OF DIAGNOSTICS AND TREATMENT OF DEMENTIA PATIENTS IN CLINICAL PRACTICE. Alzheimer's and Dementia, 2017, 13, P510.	0.8	0
121	[P3â€“223]: GENETIC MUTATIONS IN EARLYâ€ONSET DEMENTIA: REPORT FROM THE MEMORY CLINIC FROM SERBIA. Alzheimer's and Dementia, 2017, 13, P1023.	0.8	0
122	P2â€311: EARLY ONSET DEGENERATIVE DEMENTIAS: ETIOLOGICAL CLASSIFICATION AND DEMOGRAPHIC CHARACTERISTICS IN SERBIAN TERTIARY REFERRAL CENTER. Alzheimer's and Dementia, 2018, 14, P801.	0.8	0
123	Screening for gene mutation in early onset Alzheimerâ€™s disease and frontotemporal dementia: Report from a Serbian tertiary referral center. Alzheimer's and Dementia, 2020, 16, e041807.	0.8	0
124	Perspectives on the pharmacological management of dystonia. Expert Opinion on Pharmacotherapy, 2021, 22, 1555-1566.	1.8	0
125	Autonomic nervous systemâ€”Anatomy, physiology, biochemistry. International Review of Movement Disorders, 2021, , 1-17.	0.1	0
126	Novel PANK2 mutation identified in patient with pantothenate kinase-associated neurodegeneration. Srpski Arhiv Za Celokupno Lekarstvo, 2020, 148, 203-206.	0.2	0